Understand their similarities and differences of agents targeting the IL-23 pathway in #CrohnsDisease.
Discover the key phase 3 and head-to-head trials, and their positioning as a Crohn's disease treatment, with this #EdsChoice review.
👉https://buff.ly/qgRoA1H
#GastroSky #MedSky #IL23